A major new analysis from REBOOT (Treatment with Beta-blockers after Myocardial Infarction without Reduced Ejection Fraction) clinical trial, an international study coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published at the European Heart Journal has revealed important sex-specific differences in the effects of beta-blockers following heart attacks, raising questions about long-standing treatment practices.
The analysis uncovers notable sex-specific differences: while men experienced no benefit or risk when treated with beta-blockers, women treated with Beta-blockers had a significant increased risk of death, reinfarction, or hospitalization for heart failure compared to women not receiving the drug. Women treated with beta-blockers had a 2.7% higher absolute risk of mortality than those not treated with beta-blockers during the 3.7 years of follow-up of the study.
Distributed Biomedical Imaging Network